Citi Reiterates Buy on MetLife

Citi is out with its report today on MetLife MET, reiterating Buy. In a note to clients, Citi writes, "We rate the shares of MetLife as Buy/Medium Risk (1M). The company possesses the strongest long-term growth potential of any U.S. life insurer owing to its leading market positions, household brand-name awareness, and solid financial strength. With the acquisition of ALICO it has established a worldwide presence for its products led by key businesses in Japan, Mexico, Poland, Korea and the U.K." Citi maintains a $55 PT on MET. Shares of MET closed Friday at $41.21, up 3.52% from Thursday's close.